Preclinical pharmacokinetics of TPN729MA, a novel PDE5 inhibitor, and prediction of its human pharmacokinetics using a PBPK model

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Acta Pharmacologica Sinica

• Publication date

  2015-11-23

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/aps.2015.118PMID 26592518PMCID PMC4816229
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Sildenafil improves erectile hardness in Chinese men with erectile dysfunction: a real-life study analyzed on age stratification.

  2014cited by this paper
• Characterization of preclinical in vitro and in vivo ADME properties and prediction of human PK using a physiologically based pharmacokinetic model for YQA‐14, a new dopamine D3 receptor antagonist candidate for treatment of drug addiction

  2014cited by this paper
• An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors

  2013cited by this paper
• The selectivity and potency of the new PDE5 inhibitor TPN729MA.

  2013cited by this paper
• Application of PBPK modelling in drug discovery and development at Pfizer

  2012cited by this paper
• Simulation of the pharmacokinetics of bisoprolol in healthy adults and patients with impaired renal function using whole-body physiologically based pharmacokinetic modeling

  2012cited by this paper
• From preclinical to human – prediction of oral absorption and drug–drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach in an industrial setting: a workflow by using case example

  2012cited by this paper
• Application of IVIVE and PBPK modeling in prospective prediction of clinical pharmacokinetics: strategy and approach during the drug discovery phase with four case studies

  2012cited by this paper
• ADMET considerations for phosphodiesterase-5 inhibitors

  2012cited by this paper
• Nilotinib preclinical pharmacokinetics and practical application toward clinical projections of oral absorption and systemic availability

  2012cited by this paper
• PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach.

  2011cited by this paper
• PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessement of prediction methods of human clearance.

  2011cited by this paper
• Andrology in China: current status and 10 years' progress.

  2011cited by this paper
• Simulation of Human Intravenous and Oral Pharmacokinetics of 21 Diverse Compounds Using Physiologically Based Pharmacokinetic Modelling

  2011cited by this paper
• Preclinical and Clinical Pharmacokinetics of PF-02413873, a Nonsteroidal Progesterone Receptor Antagonist

  2011cited by this paper
• Novel phosphodiesterase type 5 modulators: a patent survey (2008 – 2010)

  2011cited by this paper
• Prediction of Oral Pharmacokinetics of cMet Kinase Inhibitors in Humans: Physiologically Based Pharmacokinetic Model Versus Traditional One-Compartment Model

  2011cited by this paper
• Prediction of Human Pharmacokinetics From Preclinical Information: Comparative Accuracy of Quantitative Prediction Approaches

  2009cited by this paper
• Modelling and PBPK Simulation in Drug Discovery

  2009cited by this paper
• Pre-clinical pharmacokinetics of UK-453,061, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI), and use of in silico physiologically based prediction tools to predict the oral pharmacokinetics of UK-453,061 in man.

  2008cited by this paper
• Pre-clinical pharmacokinetics of UK-453,061, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI), and use of in silico physiologically based prediction tools to predict the oral pharmacokinetics of UK-453,061 in man

  2008cited by this paper
• Interspecies Prediction of Human Drug Clearance Based on Scaling Data from One or Two Animal Species

  2007cited by this paper
• The Prediction of Drug Metabolism, Tissue Distribution, and Bioavailability of 50 Structurally Diverse Compounds in Rat Using Mechanism-Based Absorption, Distribution, and Metabolism Prediction Tools

  2007cited by this paper
• Prediction of Human Pharmacokinetics Using Physiologically Based Modeling: A Retrospective Analysis of 26 Clinically Tested Drugs

  2007cited by this paper
• Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions.

  2006cited by this paper
• A Novel Strategy for Physiologically Based Predictions of Human Pharmacokinetics

  2006cited by this paper
• Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases.

  2005cited by this paper
• A NOVEL MODEL FOR PREDICTION OF HUMAN DRUG CLEARANCE BY ALLOMETRIC SCALING

  2005cited by this paper
• The Clinical Pharmacokinetics of Phosphodiesterase‐5 Inhibitors for Erectile Dysfunction

  2005cited by this paper
• Volume of distribution at steady state for a linear pharmacokinetic system with peripheral elimination.

  2004cited by this paper
• Pharmacology of phosphodiesterase 5 inhibitors.

  2003cited by this paper
• Molecular mechanisms and pharmacokinetics of phosphodiesterase-5 antagonists

  2003cited by this paper
• PHARMACOLOGY OF PHOSPHODIESTERASE‐5 INHIBITORS

  2002cited by this paper
• Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution.

  2002cited by this paper
• Predicting the impact of physiological and biochemical processes on oral drug bioavailability.

  2001cited by this paper
• A compartmental absorption and transit model for estimating oral drug absorption.

  1999cited by this paper

• Evaluation of Safety and Pharmacokinetics of DDCI-01, a Phosphodiesterase Type 5 Inhibitor, in Healthy Participants

  2025cites this paper
• An overview of conventional and investigational phosphodiesterase 5 inhibitors for treating erectile dysfunction and other conditions

  2024cites this paper
• Drug-like properties of serial phenanthroindolizidine alkaloid compounds: ADMET characteristic prediction and validation

  2024cites this paper
• Physiologically based absorption modeling to predict the bioequivalence of two cilostazol formulations

  2023cites this paper
• Pan-Genomics of Escherichia albertii for Antibiotic Resistance Profiling in Different Genome Fractions and Natural Product Mediated Intervention: In Silico Approach

  2023cites this paper
• Absorption, distribution, metabolism, and excretion of [14C]TPN729 after oral administration to rats

  2022cites this paper
• Physiologically based pharmacokinetic modelling and simulation to predict the plasma concentration profile of schaftoside after oral administration of total flavonoids of Desmodium styracifolium

  2022cites this paper
• First-in-human study to investigate the safety and pharmacokinetics of salvianolic acid A and pharmacokinetic simulation using a physiologically based pharmacokinetic model

  2022cites this paper
• Metabolic characterization of a potent natural neuroprotective agent dendrobine in vitro and in rats

  2021cites this paper
• A Review of Current Methods for Food Effect Prediction During Drug Development

  2020cites this paper
• Species differences in the CYP3A-catalyzed metabolism of TPN729, a novel PDE5 inhibitor

  2020cites this paper
• Qualification and application of liquid chromatography-quadrupole time-of-flight mass spectrometric method for the determination of carisbamate in rat plasma and prediction of its human pharmacokinetics using physiologically based pharmacokinetic modeling

  2020cites this paper
• Species differences in the CYP3A-catalyzed metabolism of TPN729, a novel PDE5 inhibitor

  2020cites this paper
• Quantitative Analysis of Tozadenant Using Liquid Chromatography-Mass Spectrometric Method in Rat Plasma and Its Human Pharmacokinetics Prediction Using Physiologically Based Pharmacokinetic Modeling

  2019influential citation
• Building in-house PBPK modelling tools for oral drug administration from literature information

  2019cites this paper
• The ADME profile of the fungicide tricyclazole in rodent via the oral route: A critical review for human health safety assessment.

  2019cites this paper
• Pharmacotherapy for erectile dysfunction in diabetic males

  2018cites this paper
• Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration–Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics

  2018cites this paper
• Treatment of Erectile Disorder

  2017cites this paper
• Characterization of TPN729 metabolites in humans using ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry.

  2016cites this paper
• Innovative trends and perspectives for erectile dysfunction treatment: A systematic review

  2016cites this paper